Literature DB >> 25789536

The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value.

Uiju Cho1, Hee Eun Kim, Woo Jin Oh, Min-Kyung Yeo, Byung Joo Song, Ahwon Lee.   

Abstract

Markers of proliferation are considered to have prognostic importance in breast cancer (BC). The Ki-67 index has been reported as a prognostic factor, but standardized cutoff values and counting methods are not yet established. We assayed the Ki-67 labeling index (LI) of 589 consecutive operable BC patients who underwent surgical resection. Ki-67 immunostaining was performed, and the LI was manually counted using an image processing program. We also compared the manual cell count (MCC) of Ki-67 to the whole-section eyeballed estimate count (EEC). Univariate survival analysis showed statistically significant differences in long-term BC-specific survival in the following factors: tumor size, histologic grade, nuclear grade, lymph node metastasis stage, estrogen receptor, progesterone receptor, human epidermal growth factor-2 (HER2) status, and intrinsic type (P<0.05). The MCC and EEC Ki-67 evaluations were statistically well correlated (Pearson correlation=0.683, P<0.001). Their agreement rate was highest at a 20% cutoff (κ-coefficient=0.464). With cutoff values of 14% and 20%, high Ki-67 LI was associated with poor BC-specific survival (P=0.028 and 0.012, respectively), and a 20% cutoff had a higher hazard ratio. High Ki-67 LI with a 20% cutoff was also associated with poor survival in the hormone receptor-positive and lymph node-positive subgroups (P=0.015 and 0.016, respectively). In conclusion, Ki-67 LI had prognostic significance, especially in hormone receptor-positive and lymph node-positive BC patients. EEC was relatively reliable counting method with a higher cutoff value. We suggest that the 20% cutoff value be the preferable value in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25789536     DOI: 10.1097/PAI.0000000000000164

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

1.  Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer.

Authors:  Min-Kyung Yeo; Hee Eun Kim; Sung Hun Kim; Byung Joo Chae; Byung Joo Song; Ahwon Lee
Journal:  J Clin Pathol       Date:  2017-03-15       Impact factor: 3.411

2.  Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort.

Authors:  Giancarlo Marra; Marco Oderda; Giorgio Calleris; Alessandro Marquis; Federica Peretti; Andrea Zitella; Marco Moschini; Rafael Sanchez-Salas; Robert Jeffrey Karnes; Burkhard Kneitz; Martin Spahn; Donatella Pacchioni; Paolo Gontero
Journal:  Transl Androl Urol       Date:  2022-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.